Vontobel Holding
ARQT icon

Vontobel Holding’s Arcutis Biotherapeutics ARQT Stock Holding History

Vontobel Holding’s Portfolio ARQT Stock Details ARQT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$4.02M Buy
153,242
+118,632
+343% +$2.76M 0.01% 494
2026
Q1 		$815K Buy
34,610
+4,606
+15% +$118K ﹤0.01% 696
2025
Q4 		$871K Buy
30,004
+16,648
+125% +$426K ﹤0.01% 795
2025
Q3 		$252K Hold
13,356
– – ﹤0.01% 1160
2025
Q2 		$187K Hold
13,356
– – ﹤0.01% 1181
2025
Q1 		$209K Buy
+13,356
New +$188K ﹤0.01% 1006
2024
Q2 		– Sell
-21,000
Closed -$208K – 1078
2024
Q1 		$208K Hold
21,000
– – ﹤0.01% 994
2023
Q4 		$67.8K Sell
21,000
-28,191
-57% -$76.6K ﹤0.01% 1060
2023
Q3 		$261K Buy
49,191
+21,125
+75% +$180K ﹤0.01% 936
2023
Q2 		$267K Buy
28,066
+5,312
+23% +$59K ﹤0.01% 943
2023
Q1 		$250K Buy
22,754
+2,371
+12% +$34.3K ﹤0.01% 932
2022
Q4 		$287K Buy
20,383
+9,867
+94% +$172K ﹤0.01% 899
2022
Q3 		$201K Buy
+10,516
New +$238K ﹤0.01% 950

Other funds holding ARQT

SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Vontobel Holding's ARQT Position: Q2 2026 in Review

Vontobel Holding increased its Arcutis Biotherapeutics (ARQT) stake by 343% in Q2 2026, buying an estimated $2.76M and bringing the position to 153,242 shares worth $4.02M. The position accounts for 0.01% of the portfolio, ranked #494.

Vontobel Holding first reported a position in ARQT in Q3 2022 and has held it in 13 quarters since. 272 funds tracked by Wall St. Rank hold ARQT as of Q2 2026.

  • Vontobel Holding held 153,242 shares of Arcutis Biotherapeutics worth $4.02M as of Q2 2026.
  • Vontobel Holding bought 118,632 Arcutis Biotherapeutics shares in Q2 2026, an estimated $2.76M.
  • Arcutis Biotherapeutics made up 0.01% of Vontobel Holding's portfolio in Q2 2026, its #494 holding.
  • Vontobel Holding first reported a position in Arcutis Biotherapeutics in Q3 2022 and has held it in 13 quarters since.
  • 272 funds tracked by Wall St. Rank held Arcutis Biotherapeutics as of Q2 2026.

Based on Vontobel Holding's 13F filing for Q2 2026, filed 3 Aug 2026.